RNA-based vaccines

Vaccine

Volumn 30, Issue 30, 2012, Pages 4414-4418

  Ulmer, Jeffrey B ^a   Mason, Peter W ^a   Geall, Andrew ^a   Mandl, Christian W ^a  

^a Novartis Vaccines Cambridge   (United States)

Author keywords

Nucleic acid vaccine; Viral vector

Indexed keywords

ADENOVIRUS VECTOR; CYTOMEGALOVIRUS VACCINE; DNA VACCINE; GROWTH HORMONE RELEASING FACTOR; LIVE VACCINE; MELANOMA VACCINE; NEUTRALIZING ANTIBODY; NUCLEIC ACID VACCINE; PLASMID DNA; RNA VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VACCINE; VETERINARY DRUG; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR; WEST NILE VACCINE;

ANTIBODY RESPONSE; ANTIGEN EXPRESSION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOMEGALOVIRUS; DENDRITIC CELL; DNA IMMUNIZATION; DOG; ELECTROPORATION; FISH; GENE TARGETING; GENE THERAPY; HORSE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; INFECTIOUS HEMATOPOIETIC NECROSIS; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; REPLICON; REVIEW; RNA IMMUNIZATION; SWINE; VETERINARY MEDICINE; VIRUS ENTRY; VIRUS PARTICLE;

ANIMALS; CLINICAL TRIALS AS TOPIC; GENETIC VECTORS; HUMANS; PLASMIDS; REPLICON; RNA; VACCINES, DNA;

EID: 84862015339     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.04.060     Document Type: Review

References (66)

1. Rappuoli R., Mandl C.W., Black S., De Gregorio E. Vaccines for the twenty-first century society. Nature Reviews Immunology 2011, 11(12):865-872.
2. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259(5102):1745-1749.
3. Ferraro B., Morrow M.P., Hutnick N.A., Shin T.H., Lucke C.E., Weiner D.B. Clinical applications of DNA vaccines: current progress. Clinical Infectious Diseases 2011, 53(3):296-302.
4. Lara A.R., Ramirez O.T. Plasmid DNA production for therapeutic applications. Methods in Molecular Biology 2012, 824:271-303.
5. Davis B.S., Chang G.J., Cropp B., Roehrig J.T., Martin D.A., Mitchell C.J., et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. Journal of Virology 2001, 75(9):4040-4047.
6. Garver K.A., LaPatra S.E., Kurath G. Efficacy of an infectious hematopoietic necrosis (IHN) virus DNA vaccine in Chinook Oncorhynchus tshawytscha and sockeye O. nerka salmon. Diseases of Aquatic Organisms 2005, 64(1):13-22.
7. Grosenbaugh D.A., Leard A.T., Bergman P.J., Klein M.K., Meleo K., Susaneck S., et al. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. American Journal of Veterinary Research 2011, 72(12):1631-1638.
8. Draghia-Akli R., Li X., Schwartz R.J. Enhanced growth by ectopic expression of growth hormone releasing hormone using an injectable myogenic vector. Nature Biotechnology 1997, 15(12):1285-1289.
9. Sardesai N.Y., Weiner D.B. Electroporation delivery of DNA vaccines: prospects for success. Current Opinion in Immunology 2011, 23(3):421-429.
10. Lori F., Weiner D.B., Calarota S.A., Kelly L.M., Lisziewicz J. Cytokine-adjuvanted HIV-DNA vaccination strategies. Springer Seminars in Immunopathology 2006, 28(3):231-238.
11. Belisle S.E., Yin J., Shedlock D.J., Dai A., Yan J., Hirao L., et al. Long-term programming of antigen-specific immunity from gene expression signatures in the PBMC of rhesus macaques immunized with an SIV DNA vaccine. PLoS One 2011, 6(6):e19681.
12. Hirao L.A., Hokey D.A., Morrow M.P., Jure-Kunkel M.N., Weiner D.B. Immune modulation through 4-1BB enhances SIV vaccine protection in non-human primates against SIVmac251 challenge. PLoS One 2011, 6(9):e24250.
13. Rollier C.S., Reyes-Sandoval A., Cottingham M.G., Ewer K., Hill A.V. Viral vectors as vaccine platforms: deployment in sight. Current Opinion in Immunology 2011, 23(3):377-382.
14. Vaccari M., Poonam P., Franchini G. Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV. Expert Review of Vaccines 2010, 9(9):997-1005.
15. Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., et al. Direct gene transfer into mouse muscle in vivo. Science 1990, 247(4949 Pt 1):1465-1468.
16. Martinon F., Krishnan S., Lenzen G., Magne R., Gomard E., Guillet J.G., et al. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. European Journal of Immunology 1993, 23(7):1719-1722.
17. Pascolo S. Messenger RNA-based vaccines. Expert Opinion on Biological Therapy 2004, 4(8):1285-1294.
18. Hoerr I., Obst R., Rammensee H.G., Jung G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. European Journal of Immunology 2000, 30(1):1-7.
19. Carralot J.P., Probst J., Hoerr I., Scheel B., Teufel R., Jung G., et al. Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines. Cellular and Molecular Life Sciences 2004, 61(18):2418-2424.
20. Johanning F.W., Conry R.M., LoBuglio A.F., Wright M., Sumerel L.A., Pike M.J., et al. A Sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expression in vivo. Nucleic Acids Research 1995, 23(9):1495-1501.
21. Zhou X., Berglund P., Rhodes G., Parker S.E., Jondal M., Liljestrom P. Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine 1994, 12(16):1510-1514.
22. Granstein R.D., Ding W., Ozawa H. Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA. Journal of Investigative Dermatology 2000, 114(4):632-636.
23. Conry R.M., LoBuglio A.F., Wright M., Sumerel L., Pike M.J., Johanning F., et al. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Research 1995, 55(7):1397-1400.
24. Kreiter S., Selmi A., Diken M., Koslowski M., Britten C.M., Huber C., et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Research 2010, 70(22):9031-9040.
25. Ying H., Zaks T.Z., Wang R.F., Irvine K.R., Kammula U.S., Marincola F.M., et al. Cancer therapy using a self-replicating RNA vaccine. Nature Medicine 1999, 5(7):823-827.
26. Zhou W.Z., Hoon D.S., Huang S.K., Fujii S., Hashimoto K., Morishita R., et al. RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization. Human Gene Therapy 1999, 10(16):2719-2724.
27. Roesler E., Weiss R., Weinberger E.E., Fruehwirth A., Stoecklinger A., Mostbock S., et al. Immunize and disappear-safety-optimized mRNA vaccination with a panel of 29 allergens. The Journal of Allergy and Clinical Immunology 2009, 124(5). 1070-7 e1-11.
28. Weiss R., Scheiblhofer S., Roesler E., Weinberger E., Thalhamer J. mRNA vaccination as a safe approach for specific protection from type I allergy. Expert Review of Vaccines 2012, 11(1):55-67.
29. Qiu P., Ziegelhoffer P., Sun J., Yang N.S. Gene gun delivery of mRNA in situ results in efficient transgene expression and genetic immunization. Gene Therapy 1996, 3(3):262-268.
30. Aberle J.H., Aberle S.W., Kofler R.M., Mandl C.W. Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus. Journal of Virology 2005, 79(24):15107-15113.
31. Kreiter S., Diken M., Selmi A., Tureci O., Sahin U. Tumor vaccination using messenger RNA: prospects of a future therapy. Current Opinion in Immunology 2011, 23(3):399-406.
32. Mirzayans R., Aubin R.A., Paterson M.C. Differential expression and stability of foreign genes introduced into human fibroblasts by nuclear versus cytoplasmic microinjection. Mutation Research 1992, 281(2):115-122.
33. Thorburn A.M., Alberts A.S. Efficient expression of miniprep plasmid DNA after needle micro-injection into somatic cells. Biotechniques 1993, 14(3):356-358.
34. Zabner J., Fasbender A.J., Moninger T., Poellinger K.A., Welsh M.J. Cellular and molecular barriers to gene transfer by a cationic lipid. Journal of Biological Chemistry 1995, 270(32):18997-19007.
35. Probst J., Weide B., Scheel B., Pichler B.J., Hoerr I., Rammensee H.G., et al. Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent. Gene Therapy 2007, 14(15):1175-1180.
36. Probst J., Brechtel S., Scheel B., Hoerr I., Jung G., Rammensee H.G., et al. Characterization of the ribonuclease activity on the skin surface. Genetics Vaccines Therapy 2006, 4:4.
37. Lorenz C., Fotin-Mleczek M., Roth G., Becker C., Dam T.C., Verdurmen W.P., et al. Protein expression from exogenous mRNA: uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway. RNA Biology 2011, 8(4):627-636.
38. Scheel B., Teufel R., Probst J., Carralot J.P., Geginat J., Radsak M., et al. Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. European Journal of Immunology 2005, 35(5):1557-1566.
39. Kariko K., Ni H., Capodici J., Lamphier M., Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. Journal of Biological Chemistry 2004, 279(13):12542-12550.
40. Fotin Mleczek M, Zanzinger K, Heidenreich R, Lorenz C, Thess A, Duchardt KM, et al. Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. The Journal of Gene Medicine; in press.
41. Fotin-Mleczek M., Duchardt K.M., Lorenz C., Pfeiffer R., Ojkic-Zrna S., Probst J., et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. Journal of Immunotherapy 2011, 34(1):1-15.
42. Kreiter S., Diken M., Selmi A., Diekmann J., Attig S., Husemann Y., et al. FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines. Cancer Research 2011, 71(19):6132-6142.
43. Hess P.R., Boczkowski D., Nair S.K., Snyder D., Gilboa E. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen. Cancer Immunology and Immunotherapy 2006, 55(6):672-683.
44. Pascolo S. Vaccination with messenger RNA (mRNA). Handbook of Experimental Pharmacology 2008, 183:221-235.
45. Conry R.M., LoBuglio A.F., Loechel F., Moore S.E., Sumerel L.A., Barlow D.L., et al. A carcinoembryonic antigen polynucleotide vaccine for human clinical use. Cancer Gene Therapy 1995, 2(1):33-38.
46. Weide B., Carralot J.P., Reese A., Scheel B., Eigentler T.K., Hoerr I., et al. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. Journal of Immunotherapy 2008, 31(2):180-188.
47. Yamamoto A., Kormann M., Rosenecker J., Rudolph C. Current prospects for mRNA gene delivery. European Journal of Pharmaceutics and Biopharmaceutics 2009, 71(3):484-489.
48. Jones K.L., Drane D., Gowans E.J. Long-term storage of DNA-free RNA for use in vaccine studies. Biotechniques 2007, 43(5):675-681.
49. Jackson C.A., Messinger J., Palmer M.T., Peduzzi J.D., Morrow C.D. Gene expression in the muscle and central nervous system following intramuscular inoculation of encapsidated or naked poliovirus replicons. Virology 2003, 314(1):45-61.
50. Vignuzzi M., Gerbaud S., van der Werf S., Escriou N. Naked RNA immunization with replicons derived from poliovirus and Semliki Forest virus genomes for the generation of a cytotoxic T cell response against the influenza A virus nucleoprotein. Journal of General Virology 2001, 82(Pt 7):1737-1747.
51. Mandl C.W., Aberle J.H., Aberle S.W., Holzmann H., Allison S.L., Heinz F.X. In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model. Nature Medicine 1998, 4(12):1438-1440.
52. Kofler R.M., Aberle J.H., Aberle S.W., Allison S.L., Heinz F.X., Mandl C.W. Mimicking live flavivirus immunization with a noninfectious RNA vaccine. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(7):1951-1956.
53. Harvey T.J., Anraku I., Linedale R., Harrich D., Mackenzie J., Suhrbier A., et al. Kunjin virus replicon vectors for human immunodeficiency virus vaccine development. Journal of Virology 2003, 77(14):7796-7803.
54. Edlich B., Hogdal L.J., Rehermann B., Behrens S.E. Dendritic cells transfected with Her2 antigen-encoding RNA replicons cross-prime CD8 T cells and protect mice against tumor challenge. Vaccine 2010, 28(49):7764-7773.
55. Li H.O., Zhu Y.F., Asakawa M., Kuma H., Hirata T., Ueda Y., et al. A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. Journal of Virology 2000, 74(14):6564-6569.
56. Kalhoro N.H., Veits J., Rautenschlein S., Zimmer G. A recombinant vesicular stomatitis virus replicon vaccine protects chickens from highly pathogenic avian influenza virus (H7N1). Vaccine 2009, 27(8):1174-1183.
57. Widman D.G., Frolov I., Mason P.W. Third-generation flavivirus vaccines based on single-cycle, encapsidation-defective viruses. Advances in Virus Research 2008, 72:77-126.
58. Perri S., Greer C.E., Thudium K., Doe B., Legg H., Liu H., et al. An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. Journal of Virology 2003, 77(19):10394-10403.
59. Caley I.J., Betts M.R., Irlbeck D.M., Davis N.L., Swanstrom R., Frelinger J.A., et al. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. Journal of Virology 1997, 71(4):3031-3038.
60. Gehrke R., Heinz F.X., Davis N.L., Mandl C.W. Heterologous gene expression by infectious and replicon vectors derived from tick-borne encephalitis virus and direct comparison of this flavivirus system with an alphavirus replicon. Journal of General Virology 2005, 86(Pt 4):1045-1053.
61. Wang Y., Swiecki M., McCartney S.A., Colonna M. dsRNA sensors and plasmacytoid dendritic cells in host defense and autoimmunity. Immunological Review 2011, 243(1):74-90.
62. Piggott J.M., Sheahan B.J., Soden D.M., O'Sullivan G.C., Atkins G.J. Electroporation of RNA stimulates immunity to an encoded reporter gene in mice. Molecular Medicine Report 2009, 2(5):753-756.
63. Johansson D.X., Ljungberg K., Kakoulidou M., Liljestrom P. Intradermal electroporation of naked replicon RNA elicits strong immune responses. PLoS One 2012, 7(1):e29732.
64. Weide B., Pascolo S., Scheel B., Derhovanessian E., Pflugfelder A., Eigentler T.K., et al. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. Journal of Immunotherapy 2009, 32(5):498-507.
65. + immune responses and induce clinical benefit in vaccinated patients. Molecular Therapy 2011, 19(5):990-999.
66. Bernstein D.I., Reap E.A., Katen K., Watson A., Smith K., Norberg P., et al. Randomized, double-blind, phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 2009, 28(2):484-493.